GLENMARK PHARMACEUTICALS LTD.

Glenmark Pharmaceuticals Inc., USA has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. This product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial. The launch is part of Glenmark's strategy to expand its injectables portfolio and strengthen its presence in the institutional channel. The reference drug, Zyprexa® IntraMuscular Injection, had annual sales of approximately $25.4 million for the 12 months ending May 2026, according to IQVIA® sales data. This launch aims to provide affordable treatment options to patients and healthcare providers.

Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will be the first licensed market to initiate patient enrollment, following DCGI approval. Additional enrollments are planned for Australia and South Korea, pending regulatory approvals. This trial aligns with Hengrui Pharma's ongoing parent Phase 3 trial in China and aims to gather data from diverse patient populations to support the drug's development across Glenmark's licensed markets. Trastuzumab rezetecan is a first-in-class ADC developed by Hengrui Pharma, which Glenmark licensed in September 2025.

Glenmark Pharmaceuticals Ltd announced that its manufacturing facility in Goa, India, underwent a GMP inspection by the U.S. FDA from June 22 to June 30, 2026. The inspection resulted in the issuance of a Form 483 with six observations. Notably, there were no data integrity issues reported, and all observations are procedural and not repeat findings. The company anticipates no impact on the supply of its commercial products and plans to address the observations collaboratively with the U.S. FDA within the stipulated timeline. Further updates will be provided to the stock exchanges as necessary.

Glenmark Pharmaceuticals Ltd has announced the closure of its trading window for designated persons, key managerial personnel, identified employees, and connected persons. This prohibition on trading in the company's securities will commence from July 01, 2026, and will remain in effect until the declaration of the unaudited financial results for the first quarter ended June 30, 2026, plus forty-eight hours thereafter. The specific date for the board meeting to approve these results will be communicated separately. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct.

Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial. This product is bioequivalent and therapeutically equivalent to Provepharm SAS's ProvayBlue® Injection. The market for ProvayBlue® Injection achieved approximately $19.0 million in annual sales for the 12-month period ending April 2026, according to IQVIA® data. This launch is part of Glenmark's strategy to expand its institutional portfolio and provide affordable medicine options in the U.S. market.

Glenmark Pharmaceuticals Ltd. announced the launch of its acne treatment cream, Winlevi (clascoterone 10 mg/g), in key European markets through its subsidiary Glenmark Specialty S.A. This marks Glenmark's first New Chemical Entity (NCE) launch in Europe. The product, authorized by the European Commission, is for treating acne vulgaris in adults and adolescents. Glenmark is executing direct launches in several regions and through strategic partners in others. Winlevi is a first-in-class topical androgen-receptor inhibitor, offering a new treatment option for a common dermatological condition. This launch strengthens Glenmark's dermatology portfolio and its branded business in Europe.

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd, has announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. This product is bioequivalent and therapeutically equivalent to UCB, Inc.'s Vimpat® Injection. The US market for Vimpat® Injection achieved approximately $15.2 million in annual sales for the 12 months ending April 2026. This launch is part of Glenmark's strategy to expand its differentiated product portfolio in the United States, aiming to enhance healthcare provider capabilities and improve patient access to affordable treatments.

Glenmark Pharmaceuticals Ltd announced its Q4 and FY26 financial results, with FY26 consolidated revenue growing by 27.5% YoY to ₹169,825 million. The company secured a landmark licensing deal with AbbVie for ISB 2001, receiving USD 700 million upfront. Glenmark also expanded its oncology business in India and emerging markets. RYALTRIS® recorded over 50% growth in secondary sales. Q4 FY26 revenue reached ₹37,706 million, a 15.8% YoY increase, with a PAT of ₹3,013 million.

Glenmark Pharmaceuticals Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a dividend of 250% (₹2.5 per share) on the equity share capital of the company, subject to shareholder approval. The Board meeting, held on May 29, 2026, reviewed the financial performance, with results available on the company website. Standalone revenue from operations for the year ended March 31, 2026, was ₹84,400.99 million compared to ₹92,264.09 million in the previous year. The company reported a standalone loss after tax of ₹2,007.99 million for the year ended March 31, 2026, compared to a profit of ₹16,103.50 million in the previous year.

Glenmark Pharmaceuticals Ltd's Board of Directors, in its meeting on May 29, 2026, recommended a dividend of ₹2.5 per share (face value of Re. 1 each) on the equity shares for the financial year 2025-26, subject to shareholder approval. The board also approved the audited financial results for the quarter and year ended March 31, 2026. The company's standalone revenue from operations for FY26 was ₹84,400.99 million, with a net loss after tax of ₹2,007.99 million.